Evidence map›Paper›PMID 40853631›Full record

ArticleInternational journal of cancer2026

Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic status.

Renée S J M Schmitz, Alexandra W van den Belt-Dusebout, Maartje van Seijen, Ellen A J Verschuur, Frederieke H van Duijnhoven, Michael Schaapveld, Esther H Lips, Jelle Wesseling, Marjanka K Schmidt

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renée S J M SchmitzDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Alexandra W van den Belt-DuseboutDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-7860-8839
Maartje van SeijenDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ellen A J VerschuurDutch Breast Cancer Society ('Borstkanker Vereniging Nederland'), Utrecht, The Netherlands.
Frederieke H van DuijnhovenDepartment of Surgery, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Michael SchaapveldDivision of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Esther H LipsDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jelle WesselingDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Marjanka K SchmidtDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-2228-429X

Funding

Cancer Research UK and by KWF Kankerbestrijding C38317/A24043Dutch Ministry of Health, Welfare and SportInstitutional grants of the Dutch Cancer Society (KWF Kankerbestrijding)
6 · The paper itself

Abstract

The lower all-cause mortality in women with Ductal carcinoma in situ (DCIS) compared with the general population has been hypothesized to be due to a "healthy-user effect," but this has not been studied in large cohorts. In a population-based, retrospective cohort study comprising 18,942 women with primary DCIS between 1999 and 2015 in the Netherlands, the cumulative incidence of breast cancer death (BCD) was estimated using death by other cause as a competing risk. The cause-specific mortality risk of women with DCIS was compared with that of the Dutch female population. Multivariable competing risk regression was used to quantify the effects of the method of detection and socio-economic status (SES). With 289 BCDs, the 10-year cumulative incidence of BCD was 1.3% (95% CI, 1.1-1.5). Compared to the Dutch female population, women with DCIS had a 2.1-times higher risk of BCD, but a 7% lower risk of all-cause mortality. Women with screen-detected DCIS had lower risks of BCD compared to women with non-screen-detected DCIS (subdistribution hazard ratio [sHR]:0.60, 95% CI 0.47-0.77), as did women with high SES versus low SES (sHR 0.54, 95% CI 0.30-0.97) in the first 4 years of follow-up, adjusted for age and year at diagnosis, and DCIS characteristics. In conclusion, overall mortality in women with DCIS is not higher compared to the Dutch female population, though death due to invasive breast cancer is increased. Within all women with DCIS, those with screen-detected DCIS or high SES had lower BCD and all-cause mortality, suggesting a healthy-user effect.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingEarly Detection of CancerAdultAgedCause of DeathFemaleHumansIncidenceMiddle AgedNetherlandsRetrospective StudiesSocial Classbreast cancer deathcause‐specific mortalityductal carcinoma in situ (DCIS)screeningsocio‐economic status (SES)

Identifiers

PMID40853631
PMCPMC12712357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.